INGREZZA (valbenazine) capsules

INGREZZA is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia. Brand Name: INGREZZA (valbenazine) capsules, for oral use Initial U.S. Approval: 2017. FDA approved valbenazine (brand name INGREZZA) is not (yet) registered or available in India but on request Indian patient can buy INGREZZA at the lowest price.

INGREZZA (valbenazine) capsules Price In India and Overseas
INGREZZA (valbenazine) capsules, for oral use

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

INGREZZA (valbenazine) capsules, for oral use

Valbenazine, sold under the trade name Ingrezza, is a medication used to treat tardive dyskinesia. It acts as a vesicular monoamine transporter 2 (VMAT2) inhibitor.

Approved Uses
INGREZZA® (valbenazine) capsules is a prescription medicine used to treat adults with:

• movements in the face, tongue, or other body parts that cannot be controlled (tardive dyskinesia).
• involuntary movements (chorea) of Huntington’s disease. INGREZZA does not cure the cause of involuntary movements, and it does not treat other symptoms of Huntington’s disease, such as problems with thinking or emotions.
It is not known if INGREZZA is safe and effective in children.

Valbenazine is used to treat tardive dyskinesia in adults. Tardive dyskinesia is a drug-induced neurological injury characterized by involuntary movements. The clinical trials that led to FDA approval of valbenazine were 6 weeks in duration. An industry-sponsored study has studied the use of valbenazine for up to 48 weeks, in which it was found to be safe and effective for maintaining short-term (6 week) improvements in tardive dyskinesia.

Drug (Brand / Generic): INGREZZA / valbenazine
Current Indications: tardive dyskinesia
Marketed by:: Neurocrine Biosciences, Inc
Approval Date: 2017

Dosage forms and strengths of INGREZZA (valbenazine) capsules
Capsules: 40 mg.
INGREZZA (valbenazine) capsules are available as:
40 mg Capsule: White opaque body with a purple cap, printed with ‘VBZ’ and ‘40’ in black ink.
Bottle of 30: NDC 70370-1040-1
Bottle of 90: NDC 70370-1040-2

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.